Long-Term Adjunctive Edaravone for ALS: Latest Findings

Adding IV edaravone to riluzole for a year provides no additional benefit in terms of amyotrophic lateral sclerosis progression, time to ventilation, or survival versus riluzole alone, new research shows.
Medscape Medical News

source https://www.medscape.com/viewarticle/966717?src=rss